All In Biotech

Drug Trial Radar · NCT00433017

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

24-month Randomized, Double-masked, Controlled, Multicenter, Phase II Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to AMD.

Last checked: Nov 19, 2026Latest source record: Apr 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

255

Actual

Start

May 2007

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Feb 9, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration

Conditions

  • Macular Degeneration
  • Choroidal Neovascularization

Interventions

  • Verteporfin Photodynamic TherapyDrug

    After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of the infusion.

  • RanibizumabDrug

    Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection

  • PlaceboDrug

    As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12.Time frame: Baseline and Month 12
  2. Percent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 VisitTime frame: Month 2 to Month 11

Locations

12 sites in 12 countries. Site status is shown where the registry gives one.

  • Novartis Investigative site

    Vienna, Austria

  • Novartis Investigative site

    Antwerp, Belgium

  • Novartis Investigative site

    Aalborg, Denmark

  • Novartis Investigative site

    Créteil, France

  • Novartis Investigative site

    Regensburg, Germany

  • Novartis Investigative site

    Budapest, Hungary

  • Novartis Investigative site

    Florence, Italy

  • Novartis Investigative site

    Rotterdam, Netherlands

  • Novartis Investigative site

    Warsaw, Poland

  • Novartis Investigative site

    Madrid, Spain

  • Novartis Investigative site

    Geneva, Switzerland

  • Novartis Investigative site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.